tiprankstipranks
Trending News
More News >
GeoVax Labs (GOVX)
NASDAQ:GOVX
US Market
Advertisement

GeoVax Labs (GOVX) AI Stock Analysis

Compare
933 Followers

Top Page

GOVX

GeoVax Labs

(NASDAQ:GOVX)

Rating:34Underperform
Price Target:
GeoVax Labs is navigating substantial financial and operational challenges, reflected in its low financial performance score. While there are positive developments in vaccine advancements and strategic partnerships, the negative impact of the BARDA contract termination and bearish technical indicators weigh heavily on the overall score.
Positive Factors
Clinical Studies
Additional data announcements from clinical studies with 04S1 could be positive catalysts through 2025.
Comparative Analysis
DSMB Review Suggests GEO-CM04S1 May Be Superior to mRNA Vaccine.
Vaccine Development
GEO-CM04S1 booster studies to continue, with early clinical studies showing the vaccine induces durable neutralizing antibody and T-cell-based immunity against current and future variants of SARS-CoV-2.
Negative Factors
Contract Termination
Termination of the contract will not have a long-term material effect.
Project Termination
GeoVax Labs announced it received written notification from Advanced Technology International directing GeoVax to stop work on all efforts with respect to a Rapid Response Partnership Vehicle project.

GeoVax Labs (GOVX) vs. SPDR S&P 500 ETF (SPY)

GeoVax Labs Business Overview & Revenue Model

Company DescriptionGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
How the Company Makes MoneyGeoVax Labs generates revenue through a combination of government and non-governmental grants, collaborative research and development agreements, and potential licensing deals. The company partners with various organizations and institutions to advance its vaccine candidates, often receiving funding and milestone payments in return. GeoVax also seeks to monetize its vaccine platform through licensing agreements with other biotech or pharmaceutical companies, allowing them to use the technology for their own product development. Revenue may also be derived from future product sales as vaccines progress through clinical trials and achieve regulatory approval.

GeoVax Labs Earnings Call Summary

Earnings Call Date:Aug 06, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in revenue growth, regulatory advancements for GEO-MVA, and successful fundraising efforts. However, challenges such as the termination of the BARDA contract, increased expenses, and delays in clinical trials were also noted.
Q2-2025 Updates
Positive Updates
Revenue Increase
GeoVax reported revenues of $2.5 million for the first half of 2025, a significant increase from $301,000 in the same period in 2024, primarily due to the BARDA project NextGen contract.
EMA Guidance for GEO-MVA
GeoVax received guidance from the European Medicines Agency (EMA) for an expedited development path for its GEO-MVA vaccine, allowing the company to bypass Phase I and Phase II clinical trials.
Advancements in Vaccine Manufacturing
The advanced MVA manufacturing process is expected to provide a game-changing advantage in the production of MVA-based vaccines and therapies.
Expansion of Clinical Trials
GeoVax has expanded its clinical trials for GEO-CMO4S1, including a new site at the City of Hope facility for CLL patients.
Successful Fundraising
GeoVax concluded a follow-on public offering in July, raising almost $6 million in net proceeds, boosting its cash reserves.
Negative Updates
BARDA Contract Termination
The BARDA project NextGen contract was terminated as part of the government's efficiency program, impacting future revenue streams.
Increased Expenses
Research and development expenses increased by $1.4 million or 16%, and general and administrative expenses rose by $686,000 or 27%.
Net Loss
GeoVax reported a net loss of $10.7 million for the first half of 2025, compared to a net loss of $10.9 million in the same period in 2024.
Delays in Clinical Trials
The GEO-MVA and Gedeptin trials are not expected to start until the second half of 2026, indicating potential delays in product development.
Company Guidance
During the GeoVax Second Quarter 2025 Corporate Update Call, significant guidance was provided regarding the company's strategic path forward. The European Medicines Agency (EMA) granted an expedited development path for the GEO-MVA vaccine, allowing it to skip Phase I and II trials and proceed directly to a Phase III immunobridging trial, potentially accelerating its market authorization and revenue generation. The company also reported progress on its GEO-CMO4S1 COVID-19 vaccine, specifically targeting over 40 million immunocompromised adults in the U.S. and 400 million worldwide, with ongoing Phase II trials focusing on patients with blood cancers. Financially, GeoVax reported a net loss of $10.7 million for the first half of 2025, primarily due to increased R&D expenses of $10 million, driven by the BARDA contract and the Gedeptin and GEO-MVA programs. The company ended the second quarter with $3.1 million in cash but raised an additional $6 million in a follow-on public offering in July.

GeoVax Labs Financial Statement Overview

Summary
GeoVax Labs faces significant financial challenges with no revenue growth and continuous net losses, reflecting operational and market difficulties. The company's strong cash position offsets some risks, but negative cash flows and reliance on financing indicate potential financial instability.
Income Statement
10
Very Negative
GeoVax Labs has consistently reported zero or negligible revenue, indicating a significant challenge in generating sales. The company has experienced persistent net losses with negative EBIT and EBITDA margins, reflecting operational inefficiencies and high costs relative to its revenue base.
Balance Sheet
25
Negative
The balance sheet shows a relatively strong cash position with no debt, which is a positive sign of financial prudence. However, the equity ratio is weak due to a low level of total assets and historical negative equity, posing risks to financial stability and growth potential.
Cash Flow
15
Very Negative
GeoVax Labs exhibits negative operating and free cash flow, indicating potential cash management issues. The company relies heavily on financing activities to support its operations, raising concerns about sustainability and the need for continued external funding.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue6.14M3.95M0.0081.00K385.00K1.82M
Gross Profit6.12M3.86M-20.72M24.72K-15.17M-621.46K
EBITDA-24.82M-24.88M-26.67M-13.97M-18.53M-2.79M
Net Income-24.81M-24.99M-25.97M-14.01M-18.53M-2.96M
Balance Sheet
Total Assets5.35M8.16M9.28M31.35M11.80M10.39M
Cash, Cash Equivalents and Short-Term Investments3.09M5.51M6.45M27.61M11.42M9.88M
Total Debt0.000.000.000.000.00198.06K
Total Liabilities2.53M3.11M3.52M4.75M7.43M825.00K
Stockholders Equity2.82M5.05M5.76M26.60M4.36M9.57M
Cash Flow
Free Cash Flow-27.37M-24.70M-25.22M-19.16M-11.24M-2.91M
Operating Cash Flow-27.35M-24.68M-25.17M-19.03M-11.20M-2.75M
Investing Cash Flow-48.27K-20.65K-48.95K-134.26K-47.72K-156.79K
Financing Cash Flow28.93M23.75M4.06M35.35M12.78M12.51M

GeoVax Labs Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.74
Price Trends
50DMA
0.74
Positive
100DMA
0.87
Negative
200DMA
1.44
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
48.56
Neutral
STOCH
50.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GOVX, the sentiment is Negative. The current price of 0.74 is above the 20-day moving average (MA) of 0.73, above the 50-day MA of 0.74, and below the 200-day MA of 1.44, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.56 is Neutral, neither overbought nor oversold. The STOCH value of 50.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GOVX.

GeoVax Labs Risk Analysis

GeoVax Labs disclosed 31 risk factors in its most recent earnings report. GeoVax Labs reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

GeoVax Labs Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
$13.14M0.71-162.42%-82.24%
51
Neutral
$7.85B-0.21-41.41%2.22%22.81%-2.01%
44
Neutral
$11.88M-503.80%60.64%
43
Neutral
$66.62M-39.93%186.84%89.16%
42
Neutral
$11.28M-102.18%85.26%
40
Underperform
$10.18M-64.18%3.99%
34
Underperform
$18.91M-9690.24%1943.07%80.97%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GOVX
GeoVax Labs
0.74
-3.78
-83.63%
PHIO
Phio Pharmaceuticals
1.97
-0.67
-25.38%
MBRX
Moleculin Biotech
0.39
-2.08
-84.21%
ABVC
ABVC BioPharma
2.83
2.17
328.79%
ADXN
Addex Therapeutics
8.17
-3.31
-28.83%
SNSE
Sensei Biotherapeutics
8.07
-3.93
-32.75%

GeoVax Labs Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
GeoVax Labs Faces Contract Termination for COVID-19 Vaccine
Negative
Apr 14, 2025

On April 11, 2025, GeoVax Labs received a notification from Advanced Technology International to halt work on a Phase 2B clinical trial for their GEO-CM04S1 COVID-19 vaccine. The termination of the contract was decided by BARDA for governmental convenience, impacting the company’s ongoing project and possibly its strategic positioning in vaccine development.

Spark’s Take on GOVX Stock

According to Spark, TipRanks’ AI Analyst, GOVX is a Underperform.

GeoVax Labs is navigating substantial financial and operational challenges. While the BARDA award and vaccine advancements are significant positives, the company’s financial instability, negative cash flow, and bearish technical indicators weigh heavily on its overall score. The mixed sentiment from the earnings call, highlighting both achievements and setbacks, contributes to a cautious outlook.

To see Spark’s full report on GOVX stock, click here.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 02, 2025